Preventing and treating influenza

British Medical Journal

Volumn 326, Issue 7401, 2003, Pages 1223-1224

  Stöhr, Klaus ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ADULT; CHILD; COST BENEFIT ANALYSIS; DRUG EFFICACY; EDITORIAL; ENZYME INHIBITION; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS INFECTION; WORLD HEALTH ORGANIZATION;

EID: 0037496018     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7401.1223     Document Type: Editorial

References (4)

1. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner DA, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235-40.
2. McKimm-Breschkin JL, Trivedi T, Hampson AH, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial Agents and Chemotherapy 2003 (in press).
3. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002;20:2562-78.
4. World Health Organization. Fifty-Sixth World Health Assembly. Prevention and control of influenza pandemics and annual epidemics (agenda item 14.14). Geneva: WHO, 26 May 2003. (Draft A56/63.) www.who.int/gb/EB_WHA/PDF/WHA56/ea5663.pdf (accessed 28 May 2003).